The trial builds off the previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in patients ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

In a viewpoint paper recently published in the journal The Lancet Digital Health, a team led by Stanisa Raspopovic from ...

A scientific team looks at the progress and challenges in the research and development of brain implants. New achievements in the field of this technology are seen as a source of hope for many ...

Medidata has announced the extension of its partnership of 13 years with Tigermed to enhance clinical trial processes.

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Read about the UK nursing regulator's five “key lines of enquiry” for the next phase of its pre-registration practice ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.